EP 1399470 A2 20040324 - DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS
Title (en)
DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS
Title (de)
DIPEPTIDYL-PEPTIDASE IV INHIBITOREN UND IHRE VERWENDUNG ALS ANTI-KREBSMITTEL
Title (fr)
NOUVEAUX INHIBITEURS DE DIPEPTIDYLPEPTIDASE IV ET LEURS UTILISATIONS EN TANT QU'AGENTS ANTI-CANCEREUX
Publication
Application
Priority
- EP 02754782 A 20020627
- DE 10150203 A 20011012
- DE 10154689 A 20011109
- EP 0207129 W 20020627
- EP 01114796 A 20010627
- US 36090902 P 20020228
Abstract (en)
[origin: WO03002596A2] The present invention provides a new use of DPIV-inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in treating conditions mediated by DPIV or DPIV-Iike enzymes, such as immune, autoimmune or central nervous system disorder selected from the group consisting of strokes, tumors, ischemia, Parkinson's disease and migraines. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of multiple sclerosis.
IPC 1-7
IPC 8 full level
C07D 295/18 (2006.01); A61K 31/13 (2006.01); A61K 31/40 (2006.01); A61K 31/426 (2006.01); A61K 35/00 (2006.01); A61K 38/00 (2006.01); A61K 38/04 (2006.01); A61K 38/06 (2006.01); A61K 38/07 (2006.01); A61K 38/08 (2019.01); A61K 45/00 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 17/00 (2006.01); A61P 17/02 (2006.01); A61P 19/02 (2006.01); A61P 25/00 (2006.01); A61P 25/06 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61P 37/00 (2006.01); A61P 37/06 (2006.01); A61P 43/00 (2006.01); C07D 207/04 (2006.01); C07D 207/06 (2006.01); C07D 277/04 (2006.01); C07K 5/062 (2006.01); C07K 5/08 (2006.01); C07K 5/083 (2006.01); C07K 5/087 (2006.01); C07K 5/10 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01)
CPC (source: EP US)
A61K 38/04 (2013.01 - EP); A61K 38/06 (2013.01 - EP); A61K 38/07 (2013.01 - EP); A61K 38/08 (2013.01 - EP US); A61P 3/04 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 17/02 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/06 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 35/04 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 207/04 (2013.01 - EP); C07D 277/04 (2013.01 - EP); C07D 295/185 (2013.01 - EP); C07K 5/0806 (2013.01 - EP); C07K 5/0808 (2013.01 - EP); C07K 5/081 (2013.01 - EP); C07K 5/0812 (2013.01 - EP); C07K 7/06 (2013.01 - EP)
Citation (search report)
See references of WO 03002595A2
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 03002596 A2 20030109; WO 03002596 A3 20030731; AT E385238 T1 20080215; AU 2002321135 B2 20071108; AU 2002328306 B2 20070906; AU 2002328306 B8 20080221; CA 2418543 A1 20030109; CA 2424645 A1 20030109; CN 1321682 C 20070620; CN 1464881 A 20031231; DE 60224879 D1 20080320; EP 1399470 A2 20040324; EP 1399471 A2 20040324; EP 1399471 B1 20080130; JP 2004521149 A 20040715; JP 2004534836 A 20041118; NO 20030895 D0 20030226; NO 20030895 L 20030226; NO 20030896 D0 20030226; NO 20030896 L 20030416; WO 03002595 A2 20030109; WO 03002595 A3 20030508; WO 03072556 A1 20030904
DOCDB simple family (application)
EP 0207133 W 20020627; AT 02762309 T 20020627; AU 2002321135 A 20020627; AU 2002328306 A 20020627; CA 2418543 A 20020627; CA 2424645 A 20020627; CN 02802245 A 20020627; DE 60224879 T 20020627; EP 0207124 W 20020627; EP 0207129 W 20020627; EP 02754782 A 20020627; EP 02762309 A 20020627; JP 2003508975 A 20020627; JP 2003508976 A 20020627; NO 20030895 A 20030226; NO 20030896 A 20030226